Amedisys (AMED) Lowered to Buy at BidaskClub
BidaskClub cut shares of Amedisys (NASDAQ:AMED) from a strong-buy rating to a buy rating in a research note released on Tuesday.
AMED has been the subject of a number of other research reports. Cantor Fitzgerald assumed coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a neutral rating and a $117.00 price target for the company. Royal Bank of Canada boosted their price target on shares of Amedisys to $115.00 and gave the company an outperform rating in a research note on Friday, August 3rd. Bank of America upgraded shares of Amedisys from a neutral rating to a buy rating and boosted their price target for the company from $88.00 to $97.00 in a research note on Tuesday, July 3rd. ValuEngine upgraded shares of Amedisys from a buy rating to a strong-buy rating in a research note on Monday, July 30th. Finally, Robert W. Baird boosted their price target on shares of Amedisys from $105.00 to $120.00 and gave the company a neutral rating in a research note on Thursday, October 11th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Amedisys presently has a consensus rating of Buy and an average price target of $95.38.
Shares of AMED stock opened at $108.23 on Tuesday. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of 50.43, a price-to-earnings-growth ratio of 1.67 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21. Amedisys has a 12 month low of $45.60 and a 12 month high of $127.38.
In other news, insider David B. Pearce sold 398 shares of the company’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Glenmede Trust Co. NA grew its stake in shares of Amedisys by 4.3% in the 2nd quarter. Glenmede Trust Co. NA now owns 71,559 shares of the health services provider’s stock worth $6,116,000 after acquiring an additional 2,959 shares in the last quarter. Moneta Group Investment Advisors LLC bought a new stake in shares of Amedisys in the 2nd quarter worth $181,000. Algert Global LLC bought a new stake in shares of Amedisys in the 2nd quarter worth $1,208,000. Cubist Systematic Strategies LLC grew its stake in shares of Amedisys by 1,086.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after acquiring an additional 2,172 shares in the last quarter. Finally, Piedmont Investment Advisors LLC grew its position in Amedisys by 9.3% during the second quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock valued at $570,000 after buying an additional 567 shares during the period. Hedge funds and other institutional investors own 93.29% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Recommended Story: Stock Symbol
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.